iAnthus Capital Holdings, Inc.

iAnthus Capital Holdings, Inc. is a U.S.-based cannabis enterprise that holds licenses for and actively manages cannabis cultivation, processing, and retail dispensary operations. Its diverse product portfolio encompasses both cannabis and cannabidiol (CBD) offerings. For cannabis, these include traditional biomass items like pre-rolls, various infused products such as edibles and topical creams, and a wide array of concentrates and vapeables, specifically live resins, waxes, oils, tinctures, and vape cartridges. The CBD line features topical creams, tinctures, and sprays, alongside a comprehensive range of beauty and skincare solutions, including lotions, haircare items, lip balms, and bath bombs. Beyond direct retail, the company also engages in wholesale distribution of its CBD product selection. Operationally, iAnthus maintains a significant presence, controlling or operating 32 retail dispensaries and 10 cultivation or processing facilities across eight states. Established in 2014, its corporate headquarters are located in New York, New York.

iAnthus Capital Holdings, Inc. trades as IAN.CN on CNQ. The company is classified in Healthcare / Drug Manufacturers - Specialty & Generic and reports in CAD.

The current profile places the business in Drug Manufacturers - Specialty & Generic. This section is intended to summarize the operating segments, products, geographies, and main revenue lines from official filings.

Latest available fiscal data shows $146.51M of revenue and -$40.91M of net income.

Use this area for management strategy, capital allocation priorities, target markets, and measurable goals from the latest annual report or investor presentation.

The app now provides the structure, but exact strategic claims should come from official company documents before being treated as a finished investment thesis.

iAnthus Capital Holdings, Inc. can be compared against peers such as The Cannabist Company Holdings Inc., Charlotte's Web Holdings, Inc., C21 Investments Inc., Decibel Cannabis Company Inc., 1CM Inc., InnoCan Pharma Corporation.

A complete thesis should compare growth, margins, balance-sheet risk, valuation multiples, and market position against direct competitors.

Current signals to investigate include market capitalization of $34.86M, beta of -0.70, and return on equity of +39.8%.

This section should be validated with evidence such as durable margins, brand strength, regulation, switching costs, cost advantage, distribution, or technology.

Key risks should include financial leverage, cyclicality, customer concentration, regulatory exposure, currency risk, and execution risk.

IAN.CN currently shows total debt of $227.54M and beta of -0.70. Missing data should be treated as a research gap, not as low risk.

Production-capacity detail is not available as structured data yet. For industrial, defense, semiconductor, or real-estate companies, this should be reviewed from annual reports and investor presentations.

No structured backlog field is available yet. If the company reports backlog, review the relevant filing section before adding it to the thesis.

Use this section for major contracts, product launches, construction projects, acquisitions, or strategic programs that can materially affect valuation.

No recent SEC-style filings are available for this symbol yet.

Customer concentration is not available as structured data here. Add it from official filings when a company discloses material customers or revenue concentration.

Supplier concentration and critical supply-chain dependencies are not available as structured data here. This should be researched from annual reports and risk disclosures.

Company website: https://www.ianthus.com

For US-listed stocks, verify the thesis against official filings, earnings call transcripts, and company investor relations materials.